Thrombosis Associated with Cancer Market Size | 2032

Report Description

Thrombosis Associated with Cancer Market Outlook 2032

The global thrombosis associated with cancer market size was USD XX Billion in 2023 and is projected to reach USD XX Billion by 2032, expanding at a CAGR of XX% during 2024–2032. The market growth is attributed to the increased prevalence of thrombosis associated with cancer across the globe.

Increasing awareness of the occurrence of thrombosis and cancer is boosting the thrombosis associated with cancer market. Healthcare providers are increasingly recognizing the importance of managing thrombotic complications in cancer patients. This leads to a growing demand for innovative diagnostic tools, therapeutic interventions, and preventive measures. Furthermore, the high incidence of venous thromboembolism (VTE) in cancer patients undergoing surgery or chemotherapy is fueling the market in the coming years.

• A report published by the National Institute of Health on February 27, 2023, found that venous thromboembolism is a common occurrence among patients with cancer. The report highlighted that the most frequent cancer types that cause VTE are prostate cancer, accounting for 16%, followed by breast cancer at 11.8%, and lung cancer at 10.4%.
  

  Get Free Sample Report
  

Impact of Artificial Intelligence (AI) in the Thrombosis Associated with Cancer Market

The use of artificial intelligence is likely to boost the thrombosis associated with cancer market. Artificial Intelligence (AI) is beneficial in various applications, such as streamlining diagnosis, enhancing treatment efficacy, and improving patient outcomes. Moreover, AI algorithms aid in personalized treatment planning by predicting individual patient responses to anticoagulant therapy based on genetic predispositions and tumor characteristics.

Thrombosis Associated with Cancer Market Dynamics

Get Free Sample Report

Major Drivers

Growing incidence of cancer is anticipated to drive the market during the forecast period. Factors such as the aging population, lifestyle changes, and environmental factors contribute to the growing burden of cancer and subsequently thrombosis, necessitating the need for effective management and treatment strategies. Moreover, the increasing number of deaths from cancer is further driving the market.

• According to the WHO report on February 3, 2022, around 10 million people died due to cancer in 2020 globally, accounting for nearly one in six deaths.

Existing Restraints

Limited awareness among healthcare professionals regarding the management of thrombosis associated with cancer is expected to hinder the market in the coming years. This lack of awareness results in underdiagnosis and undertreatment of thrombosis, leading to adverse clinical outcomes for cancer patients. Moreover, the challenges associated with the diagnosis of thrombosis in cancer patients are projected to hamper the market during the forecast period.

Emerging Opportunities

­Ongoing investments in research and development (R&D) activities are expected to create favorable opportunities for market players competing in the market in the coming years. Companies are capitalizing on emerging trends and unmet clinical needs to position themselves as leaders in the market. Moreover, the advancement in targeted anticoagulant therapies is specifically designed to address the unique pathophysiological mechanisms of thrombosis in cancer further propelling the market during the forecast period.

Scope of the Thrombosis Associated with Cancer Market Report

The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.

Thrombosis Associated with Cancer Market Segment Insights

Drug Class Segment Analysis

Based on drug class, the thrombosis associated with cancer market is divided into vitamin K antagonist, direct thrombin inhibitors, heparin, factor Xa inhibitors, and others. The factor Xa inhibitors segment held the major share of the market in 2023, due to their increasing adoption in the management of thrombosis associated with cancer.

Factor Xa Inhibitors such as rivaroxaban and apixaban are popular, as they reduce the risk of drug interactions as compared to traditional anticoagulants. Additionally, growing awareness among healthcare professionals about factor Xa inhibitors further boosts the segment.

The direct thrombin inhibitors segment is expected to expand at a significant growth rate in the coming years, owing to the increasing demand for personalized medicine in cancer care. Direct thrombin inhibitors offer a targeted approach to thrombosis management by directly inhibiting thrombin. Furthermore, the ongoing research efforts aimed at optimizing dosing regimens are expected to propel direct thrombin utilization.

Get Free Sample Report

Indication Segment Analysis

On the basis of indication, the global market is segregated into arterial thrombosis, venous thromboembolism, and others. The arterial thrombosis segment is anticipated to expand at a substantial CAGR during the forecast period, owing to the increasing prevalence of cardiovascular risk among cancer patients, which further exacerbates the risk of arterial thrombotic events. Moreover, the growing importance of preventing and managing arterial thrombosis in cancer patients further fuels the segment during the forecast period.

Get Free Sample Report

Regional Outlook

In terms of region, the global thrombosis associated with cancer market is classified as Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa. North America held a major market share in 2023, due to the high incidence of cancer and thrombotic complications. For instance, according to a report by the American Cancer Society, over 1.9 million new cancer cases found in the US in 2022. Moreover, the region benefits from a well-established healthcare system with access to advanced diagnostic tools and therapeutic options for managing thrombosis associated with cancer.

The market in Asia Pacific is projected to grow at a significant pace in the coming years, owing to the increasing awareness about thrombotic complications and a growing number of the cancer population. Aging population, changing lifestyles, and environmental factors are contributing to the surge in cancer cases in the region. Moreover, the adoption of innovative therapeutic approaches, including advanced cancer treatment, is further propelling the market in this region.

Get Free Sample Report